a news article talks about 3 small companies whose stocks cost less than $5. The people who are in charge of these companies are buying more of their own company's stock. This is a good sign because if they believe in their company, it might be a good investment for other people too. The names of the 3 companies are Bespoke Extracts, Galectin Therapeutics, and RENN Fund. Read from source...

The article titled 'Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying' highlights certain insider transactions involving low-cost stocks. The author's argument appears to rest on the assumption that insiders, who have access to non-public information, are likely to make transactions based on their superior knowledge. However, the article also showcases the practice of cherry-picking, which involves the selection of positive or negative data to support a predetermined conclusion. For instance, the author chose to highlight positive insider transactions while ignoring instances of negative ones. This creates a one-sided narrative and provides a limited view of the truth. Additionally, the tone of the article is somewhat optimistic and seems to encourage readers to make investment decisions based on this information. This is problematic as it can lead to irrational exuberance and further fuel the market bubble. Overall, the article lacks objectivity and provides a potentially misleading view of the situation.

Galectin Therapeutics (GALT) and RENN Fund (RCG) are two stocks that insiders are buying. Galectin Therapeutics, a biopharmaceutical firm, saw its stock rise despite posting a wider-than-expected quarterly loss. RENN Fund, a financial services firm, saw its shares rise around 7% in the past month. These stocks may offer promising opportunities, but investors must consider their risk profiles before investing. Galectin Therapeutics is more volatile and risky, while RENN Fund is less risky and offers more stability. Therefore, investors should carefully weigh the potential benefits and risks before making investment decisions.